Related Experiment Video

Updated: Jul 19, 2026

Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

Management of cardiovascular diseases with micro systems and nanotechnology

L X Kong1, Z Peng, D Sugumar

  • 1Centre for Advanced Manufacturing Research, University of South Australia, Mawson Lakes, SA 5095, Australia.

Journal of Nanoscience and Nanotechnology
|October 20, 2006
PubMed

Insights

Micro and nanotechnologies show promise for diagnosing, managing, and treating cardiovascular diseases. Exploring existing micro-technologies can accelerate development for patients.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cardiovascular Medicine

Background:

  • Cardiovascular diseases (CVDs) are a primary cause of death and illness globally.
  • Aging and obesity trends exacerbate the CVD burden worldwide.
  • Micro-technologies are rapidly advancing, offering new diagnostic and therapeutic potentials.

Purpose of the Study:

  • To highlight the potential of micro- and nanotechnologies in cardiovascular disease (CVD) care.
  • To explore the repurposing of existing micro- and nanotechnologies for CVD applications.
  • To reduce research and development time for new CVD devices and drugs.

Main Methods:

  • Review of current advancements in micro-total analysis systems (microTAS) and nanotechnology.
  • Analysis of potential applications of existing micro- and nanotechnologies in cardiovascular medicine.
  • Literature synthesis on the integration of micro/nano-devices for CVD diagnosis, management, and therapy.

Main Results:

  • Micro-total analysis systems (microTAS) and nanotechnology are poised to significantly impact CVD diagnosis, management, and therapy.
  • Repurposing technologies developed for other diseases can expedite clinical translation for cardiovascular applications.
  • Technological advancements offer a pathway to meet the growing demand for effective CVD treatments.

Conclusions:

  • Micro- and nanotechnologies represent a transformative frontier in cardiovascular medicine.
  • Strategic exploration and adaptation of existing technologies can accelerate innovation in CVD care.
  • These advancements are crucial for addressing the escalating global health challenge posed by cardiovascular diseases.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...